These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9814608)

  • 1. Updating recommendations for prevention of coronary heart disease.
    Zanchetti A
    J Hypertens; 1998 Oct; 16(10):1401-2. PubMed ID: 9814608
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventing coronary heart disease: high baseline risk strategy and cost effectiveness of guidelines.
    Mackenzie DG; Forbes J; Wild S; Rutledge P
    BMJ; 2006 Apr; 332(7544):793. PubMed ID: 16575092
    [No Abstract]   [Full Text] [Related]  

  • 3. Statins for cardiovascular prevention according to different strategies: a cost analysis.
    Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
    Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of lipid disorders for coronary heart disease prevention according to International Atherosclerosis Society recommendations].
    Idzior-Waluś B
    Przegl Lek; 1999; 56(5):372-6. PubMed ID: 10554575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced.
    Pyörälä K; Wood D
    Eur Heart J; 1998 Oct; 19(10):1413-5. PubMed ID: 9820979
    [No Abstract]   [Full Text] [Related]  

  • 6. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey.
    De Smedt D; Annemans L; De Backer G; Kotseva K; Rydèn L; Wood D; Amouyel P; Bruthans J; Cifkova R; De Sutter J; Dolzhenko M; Erglis A; Gotcheva N; Gyberg V; Laucevicius A; Lovic D; Oganov R; Pajak A; Pogosova N; Reiner Ž; Stagmo M; De Bacquer D
    Int J Cardiol; 2018 Dec; 272():20-25. PubMed ID: 30172478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Practice guidelines to physicians and their economic aspects; merits and drawbacks].
    Stehouwer CD
    Ned Tijdschr Geneeskd; 1999 Apr; 143(15):776-8. PubMed ID: 10347638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines--a missed opportunity.
    Wood D
    Atherosclerosis; 1999 May; 143 Suppl 1():S7-12. PubMed ID: 10382832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine.
    Oster G; Epstein AM
    JAMA; 1987 Nov; 258(17):2381-7. PubMed ID: 3118060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Strategy of the french cardiology association in the prevention of coronary disease].
    Vacheron A
    Arch Mal Coeur Vaiss; 1992 Feb; 85(2):165-7. PubMed ID: 1562217
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing risk for coronary heart disease: beyond Framingham.
    Cobb FR; Kraus WE; Root M; Allen JD
    Am Heart J; 2003 Oct; 146(4):572-80. PubMed ID: 14564309
    [No Abstract]   [Full Text] [Related]  

  • 13. Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable.
    Ritchie LD
    Br J Gen Pract; 2000 Sep; 50(458):693-5. PubMed ID: 11050781
    [No Abstract]   [Full Text] [Related]  

  • 14. [Primary prevention remains expensive, notwithstanding the consensus on lowering serum cholesterol levels].
    Bonneux L; Barendregt JJ
    Ned Tijdschr Geneeskd; 1999 Apr; 143(15):772-5. PubMed ID: 10347637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin and heart disease.
    Nurse Pract; 1996 Nov; 21(11):111-2. PubMed ID: 8933540
    [No Abstract]   [Full Text] [Related]  

  • 16. Forecasting cholesterol management--end of the statin gold rush?
    Crownover BK; Curtiss FR
    J Manag Care Pharm; 2006; 12(6):479-85. PubMed ID: 16925456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A concise review of the cost-effectiveness of coronary heart disease prevention.
    Brown AI; Garber AM
    Med Clin North Am; 2000 Jan; 84(1):279-97, xi. PubMed ID: 10685140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.
    Eur Heart J; 1998 Oct; 19(10):1434-503. PubMed ID: 9820987
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prevention of coronary disease in clinical practice. Guidelines of the working group of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension].
    Pyörälä K; de Backer G; Graham I; Poole-Wilson P; Wood D
    Arch Mal Coeur Vaiss; 1995 Oct; 88(10 Suppl):1493-542. PubMed ID: 8815824
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA; Simoons ML
    Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.